A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Sarajevo, 71000, Bosnia and Herzegovina
Pleven, 5800, Bulgaria
Sofia, 1431, Bulgaria
Bogota, Cundinamarca 0000, Colombia
Bogota, Cundinamarca 0000, Colombia
Plzen - Bory, 30599, Czechia
Copenhagen NV, 2400, Denmark
Brest Cédex, 29609, France
Nancy Cédex, 54035, France
Debrecen, 4032, Hungary
Szeged, 6720, Hungary
Gdansk, 80-952, Poland
Moscow, 107076, Russia
Saint Petersburg, 195067, Russia
Banská Bystrica, 975 17, Slovakia
Gangnam-Gu, Seoul 135-710, South Korea
Seoul, 120-752, South Korea
Pendik, Istanbul 34890, Turkey (Türkiye)